Table 3

Ongoing studies on colchicine for cardiovascular indications

TrialRegistrationSettingStudy typeTarget sampleDrugsPrimary outcome
LoDoCo2ACTRN12614000093684Stable CADRCT, phase 35500Colchicine 0.5 mg/dayComposite of cardiovascular death, MI, ischaemic stroke and ischaemia-driven coronary revascularisation identifier: NCT01906749ACSRCT, phase 3500Colchicine 0.5 mg/dayOverall mortality, new acute coronary syndrome and ischaemic stroke identifier: NCT03048825STEMI with PCIRandomised, blinded, double-dummy, 2×2 factorial design trial of colchicine versus placebo and spironolactone versus placebo4000Colchicine 0.5 mg/day;
spironolactone 25 mg/day
MACE at 1 year;
composite of cardiovascular death, recurrent MI, or stroke; composite of cardiovascular death or new or worsening heart failure identifier: NCT02898610Transient ischaemic attack; strokeOpen label, phase 32623Colchicine (0.5 mg/day)Recurrence of non-fatal ischaemic stroke;
non-fatal major cardiac event;
vascular death
  • The LoDoCo2 trial: Low-Dose Colchicine for secondary prevention of cardiovascular disease.

  • ACS, acute coronary syndrome; CAD, coronary artery disease; CLEAR-SYNERGY, Colchicine and Spironolactone in Patients With STEMI/SYNERGY Stent Registry; COACS, Colchicine for Acute Coronary Syndromes; CONVINCE, Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomised controlled trial; STEMI, ST-elevation myocardial infarction.